MX339797B - Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. - Google Patents

Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.

Info

Publication number
MX339797B
MX339797B MX2012007846A MX2012007846A MX339797B MX 339797 B MX339797 B MX 339797B MX 2012007846 A MX2012007846 A MX 2012007846A MX 2012007846 A MX2012007846 A MX 2012007846A MX 339797 B MX339797 B MX 339797B
Authority
MX
Mexico
Prior art keywords
posterior segment
selectively penetrating
ocular therapy
derivatives selectively
segment tissues
Prior art date
Application number
MX2012007846A
Other languages
English (en)
Spanish (es)
Inventor
L Edelman Jeffrey
M Harrison Kelly
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX339797B publication Critical patent/MX339797B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2012007846A 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. MX339797B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72820905P 2005-10-18 2005-10-18
PCT/US2006/040429 WO2007047607A2 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Publications (1)

Publication Number Publication Date
MX339797B true MX339797B (es) 2016-06-10

Family

ID=37872252

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012007846A MX339797B (es) 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
MX2007012061A MX2007012061A (es) 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007012061A MX2007012061A (es) 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.

Country Status (11)

Country Link
US (5) US8062657B2 (enExample)
EP (1) EP1937210B1 (enExample)
JP (2) JP5745208B2 (enExample)
KR (1) KR101430760B1 (enExample)
CN (1) CN101394834A (enExample)
AU (1) AU2006304416B2 (enExample)
BR (1) BRPI0613401B8 (enExample)
CA (1) CA2602577C (enExample)
MX (2) MX339797B (enExample)
NZ (1) NZ562032A (enExample)
WO (1) WO2007047607A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
KR101430760B1 (ko) * 2005-10-18 2014-08-19 알러간, 인코포레이티드 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
MX2010008874A (es) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CA2762536C (en) 2009-05-18 2019-05-21 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2785468A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012100142A2 (en) * 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
US10501779B2 (en) * 2011-05-12 2019-12-10 President And Fellows Of Harvard College Oligonucleotide trapping
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
ES2727474T3 (es) 2012-05-08 2019-10-16 Nicox Ophthalmics Inc Nanocristales de propionato de fluticasona
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3360066A1 (en) * 2015-10-07 2018-08-15 Genentech, Inc. Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
EP3675895B1 (en) * 2017-09-01 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Compositions for treating macular edema
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
AU746713B2 (en) 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
DE69827138T2 (de) * 1997-08-11 2006-02-23 Allergan, Inc., Irvine Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (es) * 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
JP4005562B2 (ja) 2001-12-12 2007-11-07 ロディア・シミ イオン化合物、ポリイオン重合体及び共重合体を含む処方物
US6873524B2 (en) * 2002-08-15 2005-03-29 Audavi Corporation Data storage device
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2516782A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
DE602005011928D1 (de) * 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
KR101430760B1 (ko) * 2005-10-18 2014-08-19 알러간, 인코포레이티드 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
JP2007309763A (ja) 2006-05-18 2007-11-29 Sumitomo Electric Ind Ltd 電線の表面欠陥検出装置

Also Published As

Publication number Publication date
JP5745208B2 (ja) 2015-07-08
EP1937210B1 (en) 2017-05-31
US20070088014A1 (en) 2007-04-19
US9820995B2 (en) 2017-11-21
WO2007047607A3 (en) 2007-11-15
US20140357609A1 (en) 2014-12-04
CA2602577C (en) 2015-03-31
US8840872B2 (en) 2014-09-23
BRPI0613401B8 (pt) 2021-05-25
BRPI0613401B1 (pt) 2020-08-04
US20120065178A1 (en) 2012-03-15
US10188665B2 (en) 2019-01-29
US20180125861A1 (en) 2018-05-10
JP2014028855A (ja) 2014-02-13
CN101394834A (zh) 2009-03-25
AU2006304416A1 (en) 2007-04-26
US20160158249A1 (en) 2016-06-09
EP1937210A2 (en) 2008-07-02
AU2006304416B2 (en) 2013-03-28
US8062657B2 (en) 2011-11-22
KR101430760B1 (ko) 2014-08-19
WO2007047607A2 (en) 2007-04-26
CA2602577A1 (en) 2007-04-26
BRPI0613401A2 (pt) 2011-01-11
US9259429B2 (en) 2016-02-16
NZ562032A (en) 2011-11-25
JP2009511632A (ja) 2009-03-19
MX2007012061A (es) 2007-12-13
KR20080055749A (ko) 2008-06-19

Similar Documents

Publication Publication Date Title
MX339797B (es) Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
TWI366471B (en) Compositions and methods for localized therapy of the eye
MX2010004366A (es) Materiales inmiscibles en agua como vehiculos para suministro de farmacos.
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
WO2007100745A3 (en) Apparatus and formulations for suprachoroidal drug delivery
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
TW200505402A (en) Ophthalmic drug delivery device
AR050964A1 (es) Derivados de polimeros de lactama
NZ596093A (en) High affinity human antibodies to human il-4 receptor
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
WO2009097468A3 (en) Drug delivery devices, kits and methods therefor
BRPI0607483A2 (pt) microimplantes para administração ocular
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
TW200603831A (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
WO2005034875A3 (en) Method and material for enhance tissue-biomaterial integration
WO2010009111A3 (en) A drug depot implantable within a synovial joint
WO2009058585A3 (en) Non-aqueous water-miscible materials as vehicles for drug delivery
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
EP2279732A3 (en) Compounds and compositions for delivering active agents
MX2021002380A (es) Conjugados de isoquinolina-esteroide y usos de los mismos.
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
PT1864668E (pt) Utilização de pró-fármacos para administração ocular intravítrea
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
WO2008027793A3 (en) Ophthalmic pharmaceutical compositions and uses thereof